LAVA Therapeutics to Delist from Nasdaq Amid Acquisition

LAVA Therapeutics ( (LVTX) ) has issued an update.

On November 13, 2025, LAVA Therapeutics announced its intention to voluntarily delist its shares from Nasdaq, following the satisfaction of conditions for a tender offer by XOMA Royalty Corporation to acquire LAVA. The tender offer saw approximately 87% of LAVA’s shares tendered, and the delisting is contingent upon the acquisition of these shares. The company also announced changes to its Board of Directors, with several directors stepping down and new appointments made, reflecting a significant shift in its governance structure. This move is expected to impact LAVA’s market presence and stakeholder relations as it transitions away from Nasdaq.

The most recent analyst rating on (LVTX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on LAVA Therapeutics stock, see the LVTX Stock Forecast page.

Spark’s Take on LVTX Stock

According to Spark, TipRanks’ AI Analyst, LVTX is a Neutral.

LAVA Therapeutics’ overall stock score is primarily impacted by its weak financial performance, characterized by persistent losses and cash flow challenges. While technical indicators show some positive trends, the company’s negative valuation metrics further weigh down the score.

To see Spark’s full report on LVTX stock, click here.

More about LAVA Therapeutics

LAVA Therapeutics N.V. is a biopharmaceutical company specializing in the development of clinical-stage bispecific gamma delta T cell engagers using its proprietary Gammabody® platform. The company focuses on targeting hematologic cancers and solid tumors, with partnerships including Johnson & Johnson and Pfizer.

Average Trading Volume: 332,471

Technical Sentiment Signal: Hold

Current Market Cap: $42.09M

Learn more about LVTX stock on TipRanks’ Stock Analysis page.